Cuvrior - (300 mg; Tablet)

Generic Name	Trientine Tetrahydrochloride	Innovator	Orphalan SA
Dosage	300 mg; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
********	*** \ *********	*** **, ****	*******	****	*** ****** *** **** (***)

Chronology Of Events